ARCA biopharma Inc Receives Additional Patent For Methods For Treatment With Bucindolol Based On Genotype Of Patient

ARCA biopharma Inc announced that U.S. Patent and Trademark Office (USPTO) has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor. The patent (USP# 8,093,286) entitled Methods for Treatment with Bucindolol Based on Genetic Targeting, provides intellectual property protection in the United States for this approach to treating patients with bucindolol.